PT  - JOURNAL ARTICLE
AU  - Amir, Carolyn M.
AU  - Kapler, Simon
AU  - Hoftman, Gil
AU  - Kushan, Leila
AU  - Zinberg, Jamie
AU  - Cadenhead, Kristin S.
AU  - Kennedy, Leda
AU  - Cornblatt, Barbara A.
AU  - Keshavan, Matcheri
AU  - Mathalon, Daniel H.
AU  - Perkins, Diana O.
AU  - Stone, William
AU  - Tsuang, Ming T.
AU  - Walker, Elaine F.
AU  - Woods, Scott W.
AU  - Cannon, Tyrone D.
AU  - Addington, Jean
AU  - Bearden, Carrie E
TI  - Substance use in youth at genetic and clinical high risk for psychosis
AID  - 10.1101/2022.12.01.22282991
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.12.01.22282991
4099  - http://medrxiv.org/content/early/2022/12/06/2022.12.01.22282991.short
4100  - http://medrxiv.org/content/early/2022/12/06/2022.12.01.22282991.full
AB  - Background Elevated rates of alcohol, tobacco, and cannabis use are observed in both patients with psychotic disorders and individuals at clinical high risk for psychosis (CHR-P), and strong genetic associations exist between substance use disorders and schizophrenia. While individuals with 22q11.2 deletion syndrome (22qDel) are at increased genetic risk for psychosis, initial evidence suggests that they have strikingly low rates of substance use. In the current study, we aimed to directly compare substance use patterns and their neurobehavioral correlates in genetic and clinical high-risk cohorts.Methods Data on substance use frequency and severity, clinical symptoms and neurobehavioral measures were collected at baseline and at 12-month follow-up visits in two prospective longitudinal cohorts: participants included 89 22qDel carriers and 65 age and sex-matched typically developing (TD) controls (40.67% male, Mage=19.26 ± 7.84 years) and 1288 CHR-P youth and 371 matched TD controls from the North American Prodrome Longitudinal Study-2 and 3 (55.74% male; Mage=18.71 ± 4.27 years). Data were analyzed both cross-sectionally and longitudinally using linear mixed models.Results Controlling for age, sex, and site, CHR-P individuals had significantly elevated rates of tobacco, alcohol, and cannabis use relative to TD controls, whereas 22qDel had significantly lower rates. Increased substance use frequency and severity in CHR-P individuals was associated with increased positive psychosis symptom severity, dysphoric mood, social functioning, and IQ, while higher social anhedonia was associated with lower substance use frequency and severity, across all domains at baseline. These patterns persisted when we investigated these relationships longitudinally over one-year. CHR-P youth exhibited significantly increased positive psychosis symptoms, dysphoric mood, social anhedonia, and IQ compared to 22qDel carriers, and significantly higher social functioning and lower rates of autism spectrum disorder (ASD) compared to 22qDel carriers, both at baseline and at one year follow-up.Conclusions Individuals at genetic and clinical high risk for psychosis have strikingly different patterns of substance use. Factors such as increased neurodevelopmental symptoms (lower IQ, higher rates of ASD) and poorer social functioning in 22qDel may help explain this distinction from substance use patterns observed in CHR-P individuals.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the National Institute of Mental Health (grant U01MH081984 to Dr Addington; grants U01 MH081928; P50 MH080272; Commonwealth of Massachusetts SCDMH82101008006 to Dr Seidman; grants R01 MH60720, U01 MH082022 and K24 MH76191 to Dr Cadenhead; grant MH081902 to Dr Cannon; grant U01MH082004-01A1 to Dr Perkins; grant U01MH081988 to Dr. Walker; grant U01MH082022 to Dr. Woods; UO1 MH081857-05 grant to Dr Cornblatt; R01 MH085953 to Dr. Bearden, and U01MH101779 to Dr. Bearden.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of The University of California, Los Angeles gave ethical approval for this work. The Institutional Review Board of Emory University gave ethical approval for this work. The Institutional Review Board of Harvard University gave ethical approval for this work. The Institutional Review Board of the University of Calgary in Canada gave ethical approval for this work. The Institutional Review Board of the University of California, San Diego gave ethical approval for this work. The Institutional Review Board of the University of North Carolina at Chapel Hill gave ethical approval for this work. The Institutional Review Board of Yale University gave ethical approval for this work. The Institutional Review Board of Zucker Hillside Hospital gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors